Hinge Health, Inc.
HNGE
$113.90
+1.96%
Hinge Health, Inc. operates a digital healthcare platform that combines AI-powered motion tracking, wearable sensors, and licensed physical therapists to treat and prevent chronic musculoskeletal (MSK) conditions, selling primarily to self-insured employers and health plans as a cost-containment benefit within the U.S. healthcare information services industry. The company is a category leader in digital MSK care, differentiated by its proprietary patient movement dataset and clinical outcomes evidence, positioning it as a platform-style vendor rather than a point-solution app in a market that also includes virtual physical therapy and traditional in-person care. The current investor narrative centers on a post-IPO inflection story: Hinge Health came public in May 2025, and its 2026 results have shown revenue accelerating to 53% year-over-year growth with GAAP profitability, prompting management to raise guidance and analysts to debate whether the durable growth and expanding margins justify a premium multiple. The debate has shifted from 'can it be profitable' to 'how large is the addressable MSK market and how defensible is the AI moat,' with bulls pointing to the proprietary movement data and 86% gross margins, and skeptics warning that growth is increasingly priced in amid fierce competition from digital health peers and traditional physical therapy providers.…
HNGE
Hinge Health, Inc.
$113.90
Related headlines
Investment Opinion: Should I buy HNGE Today?
The synthesized recommendation is Hold, with a bias toward accumulating on pullbacks. The core thesis is that HNGE is a high-quality growth story with 53% revenue growth, 86% gross margins, and GAAP profitability, but the current valuation already reflects these strengths, as the average analyst target of $112.13 is only 0.5% above the current price. The analyst consensus rating of Buy (mean 1.53) supports the quality of the franchise, but the limited upside to the average target suggests waiting for a better entry point. Supporting evidence includes the 53% YoY revenue growth in Q2 2026, a 20.5% net margin, $287M in trailing free cash flow, and a debt-to-equity ratio of 0.021. However, the forward P/E of 36.5x and EV/sales of 11.8x are rich compared to the broader healthcare sector, and the stock's 144.8% YTD gain has already captured much of the near-term optimism. The biggest risks are a slowdown in revenue growth, increased competition, and multiple compression. The rating would upgrade to Buy if the stock pulls back to the $90-$95 range (analyst low target) or if revenue growth accelerates above 60% with margin expansion. It would downgrade to Sell if revenue growth decelerates below 30% or if gross margins fall below 80%. Relative to its history and peers, HNGE appears fairly valued to slightly overvalued, given the premium multiples and the stock trading near its 52-week high.
Sign up to view all
HNGE 12-Month Price Forecast
HNGE is a high-quality growth company with exceptional fundamentals, but the stock's valuation and recent price appreciation suggest that much of the good news is already reflected. The base case (55% probability) assumes continued strong execution with a target range of $105-$120, while the bull and bear cases are balanced at 25% and 20%, respectively. The key tension is between the company's ability to sustain >50% growth and the market's willingness to pay a premium multiple. I would upgrade to bullish if the stock pulls back to the $90-$95 range or if revenue growth accelerates, and downgrade to bearish if growth decelerates below 30% or margins compress.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Hinge Health, Inc.'s 12-month outlook, with a consensus price target around $114.31 and implied upside of +0.4% versus the current price.
Average Target
$114.31
0 analysts
Implied Upside
+0.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$90 - $140
Analyst target range
Bulls vs Bears: HNGE Investment Factors
The bull case rests on HNGE's exceptional growth (53% YoY), expanding margins (86.4% gross, 20.5% net), and a debt-free balance sheet, which together justify a premium multiple. However, the bear case is equally compelling: the stock has already doubled in the past year, trades at 11.8x EV/sales, and sits just below its 52-week high with an average analyst target that offers virtually no upside. The most important tension is whether HNGE can sustain >50% growth into 2027; if it does, the valuation will prove reasonable, but any deceleration could lead to multiple compression. Currently, the evidence slightly favors the bulls given the strong fundamentals and momentum, but the risk/reward is balanced at these levels.
Bullish
- Hyper-growth with GAAP profitability: Q2 2026 revenue grew 53% YoY to $212.8M while delivering $43.7M of net income (20.5% net margin) and $40.4M operating income (19.0% margin). This combination of >50% growth and positive GAAP earnings is rare in digital health and demonstrates operating leverage.
- Best-in-class gross margins: Gross margin reached 86.4% in Q2 2026, up from 84.6% in Q1 and 81.9% in Q3 2025, reflecting a software-like cost structure. The 79.8% trailing gross margin and $287M TTM free cash flow underscore strong unit economics.
- Fortress balance sheet: Debt-to-equity is just 0.021 and the current ratio is 1.47, indicating minimal leverage and ample liquidity. This gives HNGE flexibility to invest in growth or withstand macro shocks without dilution risk.
- Analyst consensus and target upside: 16 analysts rate the stock a Buy (mean 1.53) with an average target of $112.13, essentially in line with the current $111.52 price, but the high target of $140 implies 25.5% upside. The low target of $90 suggests limited downside of ~19% from here.
Bearish
- Premium valuation leaves little room: At 6.26x trailing sales and 11.79x EV/sales, HNGE trades at a steep premium to typical healthcare services multiples. The forward P/E of 36.5x on estimated EPS of $5.29 already discounts years of strong growth, making the stock vulnerable to any slowdown.
- Growth is priced in: The stock is up 144.8% YTD and 125.1% over one year, yet the average analyst target of $112.13 is only 0.5% above the current price. This suggests the market has fully absorbed near-term expectations, and further upside requires consistent beats.
- Competitive and reimbursement risks: The digital MSK space is crowded with well-funded peers and traditional physical therapy providers. Zacks notes that fierce competition could pressure pricing and customer acquisition costs, as reflected in the 38.3% of revenue spent on sales and marketing in Q2 ($81.4M).
- Profitability history is short: HNGE only recently turned profitable, with a trailing net margin of -89.9% due to IPO-related charges in 2025. The Q2 2026 net margin of 20.5% is impressive but has not yet been proven across a full economic cycle.
HNGE Technical Analysis
Beta
—
—
Max Drawdown
-47.7%
Largest decline past year
52-Week Range
$30-$114
Price range past year
Annual Return
+128.4%
Cumulative gain past year
| Period | HNGE Return | S&P 500 |
|---|---|---|
| 1m | +19.2% | -0.2% |
| 3m | +53.8% | +5.5% |
| 6m | +155.4% | +7.1% |
| 1y | +128.4% | +12.3% |
| ytd | +150.0% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HNGE Fundamental Analysis
Quarterly Revenue
$212817000.0B
2026-06
Revenue YoY Growth
+53.0%
YoY Comparison
Gross Margin
86.4%
Latest Quarter
Free Cash Flow
$287327000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HNGE Overvalued?
PE
-8.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 6x~38x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-6.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are relatively low given HNGE's debt-to-equity of 0.021 and $287M in trailing free cash flow, but the company's short history as a public entity and reliance on a single product line (digital MSK) create concentration risk. Sales and marketing consume 38.3% of revenue, and any increase in customer acquisition costs could pressure margins. Additionally, the 2025 IPO introduced volatility, with a trailing net margin of -89.9% due to one-time charges, though recent quarters show a turnaround. Market and competitive risks are significant: HNGE faces intense competition from digital health peers and traditional physical therapy providers, and its premium valuation (11.8x EV/sales) leaves little room for error. The stock's beta is likely elevated, as evidenced by a 47.7% max drawdown, and it is sensitive to sector rotation away from high-growth healthcare names. Recent analyst commentary highlights that growth is already priced in, and any slowdown could trigger a sharp selloff. The worst-case scenario would involve a combination of decelerating revenue growth (e.g., dropping below 30%), increased competition eroding margins, and a broader market correction. In such a scenario, the stock could retrace to its 52-week low of $30.08, representing a 73% decline from the current $111.52, or to the analyst low target of $90, a 19% drop. Given the high volatility, investors should be prepared for significant drawdowns.
FAQ
The key risks include: 1) Competitive risk: intense competition in digital MSK could pressure pricing and increase customer acquisition costs, as sales and marketing already consume 38.3% of revenue. 2) Valuation risk: the premium multiple (11.8x EV/sales) leaves little room for error, and any growth deceleration could trigger multiple compression. 3) Execution risk: the company's short history as a public entity and reliance on a single product line create uncertainty. 4) Market risk: the stock's high volatility (47.7% max drawdown) and sensitivity to sector rotation could lead to sharp declines. These risks are ranked from high to medium severity.
Our 12-month forecast includes three scenarios: Bull case (25% probability) with a target range of $130-$140, assuming sustained >50% growth and margin expansion; Base case (55% probability) with a target range of $105-$120, assuming 35-45% growth and stable margins; Bear case (20% probability) with a target range of $80-$90, assuming growth slows to 20-30% and margins compress. The base case is most likely, with a target around $112, in line with the analyst average. The key assumption is that HNGE maintains its competitive edge and continues to grow above 35%.
HNGE appears fairly valued to slightly overvalued at current levels. Its forward P/E of 36.5x and EV/sales of 11.8x are premium multiples compared to the broader healthcare sector, reflecting high growth expectations. The stock trades near its 52-week high of $113.48 and has a price-to-book ratio of 9.72, indicating that the market is pricing in significant future growth. While the company's 53% revenue growth and 20.5% net margin justify a premium, the average analyst target of $112.13 suggests limited near-term upside. The valuation implies that investors expect HNGE to sustain >40% growth for several years, which may be challenging.
HNGE is a high-quality growth stock with impressive fundamentals, including 53% revenue growth, 86.4% gross margins, and GAAP profitability. However, the stock has already surged 144.8% YTD and trades at a premium valuation (11.8x EV/sales), with the average analyst target of $112.13 offering only 0.5% upside. The risk/reward is balanced at current levels, making it a good buy only for investors with a high risk tolerance and a long-term horizon who can withstand potential drawdowns. Waiting for a pullback to the $90-$95 range (analyst low target) would provide a more attractive entry point.
HNGE is more suitable for long-term investment (minimum 2-3 years) given its high growth potential and current premium valuation. The stock is not for short-term traders due to its high volatility (47.7% max drawdown) and lack of dividend. Long-term investors can benefit from the company's large addressable market, proprietary AI technology, and expanding margins, but should be prepared for periodic drawdowns. A suggested minimum holding period is 2-3 years to allow the company to execute on its growth strategy and for the valuation to normalize.